Long-term bolstering on all-inclusive survival from the MM-009 and MM-010 inapt of feeling III trials of lenalidomide coupled with dexamethasone in patients with relapsed or refractory multiple myeloma. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. Patients in both studies were randomized to accept 25 mg commonplace articulated lenalidomide or anyway placebo, coupled with 40 mg articulated dexamethasone. We adjacent a pooled update of two in the first, multicenter MM-009 and MM-010 placebo-controlled randomized inapt of feeling III trials that included 704 patients and assessed lenalidomide coupled with dexamethasone versus dexamethasone coupled with placebo in patients with relapsed/refractory multiple myeloma (MM). In this pooled rehash, using dope up to unblinding (June 2005 benefit of MM-009 and August 2005 benefit of MM-010), treatment with lenalidomide coupled with dexamethasone significantly improved all-inclusive feedback (60.6 vs 21.9%, P<0.001), unreserved feedback anyhow (15.0 vs 2.0%, P<0.001), formerly to extending (median of 13.4 vs 4.6 months, P<0.001) and duration of feedback (median of 15.8 months vs 7 months, P<0.001) compared with dexamethasone-placebo. Low beta(2)-microglobulin and humble bone marrow plasmacytosis were associated with longer survival.
At a median bolstering of 48 months benefit of surviving patients, using dope up to July 2008, a eloquent eschew in all-inclusive survival (median of 38.0 vs 31.6 months, P=0.045) was retained undeterred by 47.6% of patients who were randomized to dexamethasone-placebo receiving lenalidomide-based treatment after ailment extending or meditate on over unblinding. In conclusion, these dope sponsorship the eloquent feedback and survival eschew with lenalidomide and dexamethasone.Leukemia pluck pluck out up stakes forward online hebdomedary, 23 July 2009; doi:10.1038/leu.2009.147.